Stock Market Watch

Two moving AMEX Stocks around a Buck: AEN and XFN

by ·




Adeona Pharmaceuticals, Inc. (AMEX:AEN) is currently trading at the high of the trading session today at a share price of $1.12 for a gain of 34.94% from yesterday’s close. This move also represents a break through prior resistance at $1.08… Get my next ALERT 100% FREE

AEN a developer of innovative disease-modifying medicines for serious illnesses, announced today that the Company’s clinical collaborator for amyotrophic lateral sclerosis (ALS),  PNA Center for Neurological Research  (PNA), reported top-line results from its pilot Phase I/II open label, three month safety study of oral high dose zinc therapy in ALS, also known as  Lou Gehrig ‘s disease. The clinical study met its primary outcome as no safety issues related to zinc therapy were observed. In addition, an average decrease in the monthly rate of disease progression was observed in the ALS patients on zinc therapy, compared to published historical controls, as well as compared to the average monthly rate of disease progression of the subjects prior to enrollment in the study.

PNA’s clinical study data was presented at the 22nd International Symposium on ALS/Motor Neurone Disease in Sydney, Australia on Wednesday, November 30, 2011 at 6:00 p.m.  (Wednesday, November 30, 2011 at 2:00 a.m. Eastern Standard Time), by David S. Saperstein, M.D., and Nicole C. Hank, M.H.S.M., from PNA.


Ten patients diagnosed with sporadic ALS and on stable doses of RILUTEK (riluzole) were enrolled in the open label, three month study of oral high dose zinc therapy. The study was conducted under an Investigational New Drug application (IND) and was registered at http://clinicaltrials.gov/ct2/show/NCT01259050.The rate of disease progression was measured by the ALS Functional Rating Scale-Revised (ALSFRS-R), a widely used, validated rating scale that assesses the progression of disability in patients with ALS, revised to also incorporate assessments of respiratory function. At baseline, the average ALSFRS-R score of these patients was 33 and the average time from symptom onset was one year.

Xfone, Inc. (AMEX:XFN) has traded as high as $.79 during today’s trading session and last traded at $.69 for a gain of 23.23% from yesterday’s close. XFN shares have traded as high as $1.84 over the past 52 weeks and at last traded price – XFN is now 62.5% off that high.

On November 15, XFN announced an increase in revenue from the Company’s Fiber-To-The-Premise (FTTP) business as it grew 30% to $3.4 million in the quarter ended September 30, 2011, as compared to approximately $2.6 million in the third quarter of 2010. Sequentially, FTTP revenues increased 12.4% as compared to the second quarter of 2011. FTTP revenues represented 23.4% of total revenues for the third quarter of 2011 as compared to 17.6% of total revenues for the third quarter of 2010.

Xfone is a provider of high speed broadband services, including Internet access, digital cable TV programming and local and long distance telephone service to residential and business customers in northern Texas and southeastern Louisiana. Xfone’s Fiber-To-The-Premise (FTTP) network provides one of the fastest internet connections available. The Company currently has operations in Texas, Mississippi and Louisiana and also serves customers in Arizona, Colorado, Kansas, New Mexico and Oklahoma. For the company’s website, please visit: www.xfone.com.

More Posts by this author

Post Written By: Oliver Crowne

Oliver Crowne is the main editor for http://www.StockPreacher.com


Ed Liston

Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing.

You may also like...